Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

FED

Sponsor class

Conditions

Spinal Cord Injury (=3 Years)
Sublesional Bone Loss Secondary to SCI

Interventions

DRUG: Romosozumab
DRUG: Denosumab
DRUG: Placebo

Sponsor

VA Office of Research and Development

Collaborators

[object Object]